Clinical trials in Murcia – page 3

444 clinical trials in Murcia, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in SpainEnsayosClinicos.es

Murcia at a glance

444

clinical trials

Research sites3

Quick filters

444 trials in Murcia

Open in trial search

Lupus nephritis

Recruiting

Safety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)

InvestigationalNo placebo

Safety and early efficacy of TranspoCART19 CAR‑T CD19 therapy in patients with refractory lupus nephritis (Phase I‑IIa)

InvestigationalNo placebo

Spain

Participants:18–64 years
Substances:Transpocart19
Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Contact Research Centre

Chronic myeloid leukaemia

Recruiting

Safety and effectiveness of ponatinib and asciminib in chronic myeloid leukemia patients resistant to these drugs

Registered drugNo placebo

Safety and effectiveness of ponatinib and asciminib in chronic myeloid leukemia patients resistant to these drugs

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Ponatinib
Sponsor:Grupo Espanol De Leucemia Mieloide Cronica (GELMC)

Contact Research Centre

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Ruxolitinib
Sponsor:Novartis Pharma AG

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo

Cemsidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Sponsor:C4 Therapeutics Inc.

Contact Research Centre

Hormone-dependent prostate cancer

Recruiting

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Apalutamide

Contact Research Centre

Pancreatic failure

Recruiting

NHS7108 for Exocrine Pancreatic Insufficiency in Adult Patients

InvestigationalNo placebo

NHS7108 for Exocrine Pancreatic Insufficiency in Adult Patients

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Amylase

Contact Research Centre

Non-small cell lung cancer+1

Recruiting

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Acute promyelocytic leukaemia

Recruiting

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo

QTX-2101 and Arsenic Trioxide in Adult Patients With Acute Promyelocytic Leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Arsenic Trioxide

Contact Research Centre

Dyslipidaemia

Recruiting

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug

Comparison of Obicetrapib and Bempedoic Acid in Patients with Dyslipidemia at High to Very High Cardiovascular Risk

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Bempedoic Acid

Contact Research Centre

Breast cancer+1

Recruiting

Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

Registered drugNo placebo

Zanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Medica Scientia Innovation Research S.L.

Contact Research Centre

Diverticulitis

Recruiting

Outpatient Treatment Without Antibiotics or with Ciprofloxacin, Cefuroxime, Cefditoren Pivoxil, Amoxicillin/Clavulanic Acid, and Metronidazole in Adults with Acute Uncomplicated Diverticulitis

Registered drugNo placebo

Outpatient Treatment Without Antibiotics or with Ciprofloxacin, Cefuroxime, Cefditoren Pivoxil, Amoxicillin/Clavulanic Acid, and Metronidazole in Adults with Acute Uncomplicated Diverticulitis

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Amoxicillin
Sponsor:Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia

Contact Research Centre

B-cell small lymphocytic lymphoma

Recruiting

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:BeOne Medicines I GmbH

Contact Research Centre

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Murcia

What the registry says about research in the country

01 Oncology - Blood Cancers

Innovative clinical trials focusing on hematologic malignancies, including studies of new therapeutic combinations for chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Research aims to evaluate novel treatment approaches and improve patient outcomes.

Chronic Myeloid Leukemia treatment optimization
Multiple Myeloma therapy combinations
Lymphoma management strategies

02 Solid Tumors

Comprehensive studies evaluating treatments for various solid tumors, including innovative approaches for breast cancer, melanoma, and gastric cancer. Research focuses on targeted therapies and immunotherapy combinations.

Advanced breast cancer treatments
Melanoma brain metastases therapy
Gastrointestinal cancer interventions

03 Neurological Conditions

Groundbreaking research in neurological disorders, particularly focusing on multiple sclerosis and acute cerebral ischemic stroke. Studies aim to evaluate new therapeutic agents and improve patient outcomes.

Stroke treatment innovations
Multiple sclerosis management
Neurological therapeutic advances

Back to Spain All countries